Please use this identifier to cite or link to this item:
https://ah.lib.nccu.edu.tw/handle/140.119/95324| 題名: | 亞洲生技醫藥產業之生產力與效率分析 The Productivity and Efficiency Analysis of Biotech Pharmaceutical Industry in Asia |
作者: | 蕭雅茹 | 貢獻者: | 李文福 蕭雅茹 |
關鍵詞: | 生技醫藥產業 隨機成本邊界 成本效率 總要素生產力 biotech pharmaceutical industry stochastic cost frontier cost efficiency total factor productivity |
日期: | 2009 | 上傳時間: | 9-五月-2016 | 摘要: | 各國視生技產業為未來發展的關鍵產業，並積極推動各項政策，使生技產業能快速成長，而生技醫藥市場是促成全球生技產業成長的主要動力，為了增加我國的競爭力，希望藉由與鄰近國家醫藥產業的比較，能更了解台灣生技醫藥產業經營績效。\r\n本研究採用Battese and Coelli (1995)隨機成本邊界法，針對2002-2007年間，日本、南韓、中國、印度與台灣等五個國家，共61家生技醫藥廠商進行實證分析，研究結果如下：(1)研發密集度增加使成本效率降低，五個國家裡，日本最具成本效率。(2)產業平均成本效率值為0.855，且有逐年惡化的趨勢。(3)整體產業平均處於遞增規模報酬階段。(4)整體而言，總要素生產力(TFP)的提升主要是因為規模成分的貢獻，其次為技術的進步，而技術效率變動率對TFP成長率為負影響。(5)各國間雖然TFP變動率不存在顯著性差異，但在規模成分、技術變動率與技術效率變動率等方面存在著顯著的差異。 Many countries regard biotechnology as a key industry for the future development. Governments often implement a variety of policies to help it grow rapidly. The biotech pharmaceutical industry is the main momentum for the growth of the global biotech industry. The objective of this paper is to measure the productivity and efficiency of the industry among Asian countries, and investigates the sources of the performance changes, and then hope to give some insight into the enhancement of the industry’s productivity. \r\nTo pursue our goal, we adopt Battese and Coelli’s (1995) stochastic frontier approach to assess 61 biotech pharmaceutical firms during 2002-2007. The main empirical results can be summarized as follows: (1) The R&D intensity is negatively related to cost efficiency; in five countries, Japan has the highest cost efficiency. (2) On average, the cost efficiency is about 0.86, and has become worsen year after year. (3)Most of time, the industry is characterized with the increasing returns to scale. (4) The growth of total factor productivity (TFP) is mainly attributed to the scale efficiency change, and technical progress accounts for a minor source. However, technical efficiency deteriorates over time. (5) Among countries, the TFP growth rates have no significant differences, but the components show apparent differences. |
參考文獻: | 醫藥產業年鑑，2005，生物技術開發中心。\r\n生技產業白皮書，2008，經濟部工務局。\r\n吳明仲 (1997)，「台灣地區製藥業生產技術效率之研究」，國立中央大學產業經濟研究所碩士論文。\r\n吳佳原 (2004)，「台灣與美國生物科技產業生產力與效率分析」，東吳大學經濟學研究所碩士論文。\r\n李曉娟 (2007)，「亞洲生技產業之總要素生產力研究」，東吳大學經濟研究所碩士論文。\r\n邱永和、胡均立及曹嘉麟 (2003)，「台灣物科技廠商之成本效率分析」，農業與經濟，第31期，55-78。\r\n邱永和、陳玉涓及曹嘉麟 (2005)，「台灣生物技術產業之效率與生產力評估」，清華科技法律與政策論叢，第2卷第2期，93-120。\r\n洪舜菁 (2005)，「兩岸生技製藥廠商績效評估—三階段評估法之應用」，國立交通大學經理管理研究所碩士論文。\r\n夏松喬 (2006)，「海外直接投資對台灣生技廠商營運績效影響之研究」，國立高雄大學經濟管理研究所碩士論文。\r\n張東生、廖振谷 (2003)，「台灣地區生技與製藥產業相對經營效率動態分析」，產業論壇，第5卷第2期，1-21。\r\n莊武仁、黃秀玲 (1998)，「台灣壽險產業規模經濟和多元經濟之研究」，淡江學報，第36期，135-158。\r\n陳詩筠 (2005)，「台灣製藥業結構、行為與績效之影響因素探討」，國立政治大學經濟研究所碩士論文。\r\n曾資婷 (2005)，「生技產業績效分析—亞洲國家為例」，東吳大學經濟研究所碩士論文。\r\n黃台心、張寶光及邱郁芳 (2009)，「應用共同成本函數探討東亞六國銀行業之生產效率」，經濟論文，第37卷第1期，61-100。\r\n鄒明釗 (2003)，「兩岸生物科技廠商之績效評估」，國立交通大學經營管理研究所碩士論文。\r\n劉祥熹、朱珮宏 (2002)，「台灣地區生技產業經營績效之研究－DEA方法與\r\nMalmquist生產力指數之應用」，產業論壇，第7卷第3期，63-100。\r\n賴士葆、陳松柏及盧冠嘉 (2004)，「台灣生物科技公司經營效率之研究」，管理與資訊學報，第9期，63-88。\r\n顏晃平 (2005)，「台灣農業生物科技廠商生產技術效率之分析－以四階段資料包絡分析法評估」，農業金融論叢，第53卷，205-224。\r\nAfriat, S. N. (1972), “Efficiency Estimation of Production Function,” International Economic Review, 13, 568-98.\r\nAigner, D. J. and S. F. Chu (1968), “On Estimation the Industry Production Function,” American Economic Review, 58, 826-39.\r\nAigner, D. J., C. A. K. Lovell and P. Schmidt (1977), “Formulation and Estimation of Stochastic Frontier Production Function Models,” Journal of Econometrics, 6, 21-37.\r\nBattese, G. E. and T. J. Coelli (1995), “A Model for Technical Inefficiency Effects in a Stochastic Frontier Production Function for Panel Data,” Empirical Economics, 20, 325-32.\r\nBauer, P. W. (1990), “Recent Developments in the Econometrics Estimation of Frontiers,” Journal of Econometrics, 46, 39-56.\r\nBlackorby, C. and R. R. Russell (1989), “Will the Real Elasticity of Substitution Please Stand Up? (A Comparison of the Allen/Uzawa and Morishima Elasticities),” American Economic Review, 79(4), 882-88.\r\nCharnes, A., W. W. Cooper and E. Rhodes (1978), “Measuring the Efficiency of Decision Making Units,” European Journal of Operational Research, 2, 429-44.\r\nChen, M. F., J. L. Hu and C. G. Ding (2005), “Efficiency and Productivity of Taiwan`s Biotech Industry,” International Journal of Biotechnology, 7(4), 307-32.\r\nDiewert, W. E. (1974), “Intertemporal Consumer Theory and the Demand for Durables,” Econometrics, 42, 497-516.\r\nFarrell, M. J. (1957), “The Measurement of Productive Efficiency,” Journal of the Royal Statistical Society, A120, 253-81.\r\nGonzalez, E. and F. Gascon (2004), “Sources of Productivity Growth in the Spanish Pharmaceutical Industry,” Research Policy, 33, 735-45.\r\nGraves, S. B. and N. S. Langowitz (1993), “Innovative Productivity and Returns To Scale in the Pharmaceutical Industry,” Strategic Management Journal, 14, 593-605.\r\nGreene, W. H. (1980), “Maximum Likelihood Estimation of Econometric Frontier Functions,” Journal of Econometrics, 13, 27-56.\r\nHall, L. A. and S. Bagchi-Sen (2002), “A Study of R&D Intensity, Innovation and Business Performance in the Canadian Biotechnology Industry,” Technovation, 22(2), 231-44.\r\nJensen, E. J. (1987), “Research Expenditures and the Discovery of New Drugs,” Journal of Industrial Economics, 36(1), 83-95.\r\nKumbhakar, S. C. and C. A. K. Lovell, (2000), Stochastic Frontier Analysis, New York: Cambridge University Press.\r\nLele, U. (2003), “Biotechnology: Opportunities and Challenges for Developing Countries,” American Journal of Agricultural Economics, 85(5), 1119-25.\r\nMeeusen, W. and J. Broeck (1977), “Efficiency Estimation from Cobb-Douglas Production Functions with Composed Error,” International Economic Review, 18, 435-44. \r\nNesta, L and P. S. Pier (2005), “Coherence of Knowledge Base and the Firm’s Innovation Performance: Evidence from the U.S. Pharmaceutical Industry,” Journal of Industrial Economics, 53(1), 123-42.\r\nPazderka, B. (1999), “Patent Protection and Pharmaceutical R&D Spending in Canada,” Canadian Public Policy, 25, 29-46.\r\nPitt, M. M. and L. F. Lee (1981), “Measurement and Sources of Technical Inefficiency in the Indonesian Weaving Industry,” Journal of Development Econometrics, 9, 43-64.\r\nRichmond, J. (1974), “Estimating the Efficiency of Production,” International Economic Review, 15, 515-21.\r\nRitter, C. and L. Simar (1997), “Pitfalls of Normal-Gamma Stochastic Frontier Models,” The Journal of Productivity Analysis, 8, 167-82.\r\nRudholm Niklas (2001), “Entry and Number of Firms in the Swedish Pharmaceuticals Market,” Review of Industrial Organization, 19, 351-64.\r\nSchmidt, P. (1976), “On the Statistical Estimation of Parametric Frontier Production Functions,” Review of Economic and Statistics, 58, 238-39.\r\nSchmidt, P. and R. C. Sickles (1984), “Production Frontiers and Panel Data,” Journal of Business and Economic Statistics, 2, 367-74.\r\nSellers, L. T. (2000), “Pharmaceutical Executive,” Executive Prophecies, 20, 60-66.\r\nShepherd, W. G. (1972), “The Elements of Market Structure,” The Review of Economic and Statistics, 54(1), 25-37.\r\nVarian, H. R. (1992), Microeconomics Analysis, 3rd ed, New York, Norton. | 描述: | 碩士 國立政治大學 經濟學系 96258003 |
資料來源: | http://thesis.lib.nccu.edu.tw/record/#G0096258003 | 資料類型: | thesis |
| Appears in Collections: | 學位論文 |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| index.html | 115 B | HTML2 | View/Open |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.